RETATRUTIDE

Retatrutide is an investigational triple hormone receptor agonist being studied for obesity, weight management and metabolic health.

Unlike medicines that target only one or two pathways, Retatrutide activates three important receptors:

GLP-1 • GIP • Glucagon

These pathways are involved in appetite, energy balance, glucose regulation and metabolism.

Potential Benefits Being Studied;

⦁ Significant Weight Reduction — clinical studies have demonstrated substantial reductions in body weight.

⦁ Reduced Appetite — targets pathways involved in appetite and food intake.

⦁ Supports Metabolic Health — being investigated for its potential effects on overall cardiometabolic health.

⦁ Improved Glucose Control — studies have shown improvements in blood-glucose regulation.

⦁ Reduced Waist Circumference — clinical research has demonstrated meaningful reductions in waist measurements.

⦁ Triple-Action Mechanism — simultaneously targets GLP-1, GIP and glucagon receptors.

⦁ Once-Weekly Research Dosing — studied as a once-weekly subcutaneous injection.

Triple-Action Approach:

GLP-1

Helps regulate appetite, food intake and glucose.

GIP

Works alongside GLP-1 and plays a role in metabolic and insulin responses.

Glucagon

Plays an important role in energy balance and metabolism.

Together, these three pathways make Retatrutide a particularly interesting area of current metabolic research.

Clinical Research:

Clinical trials investigating Retatrutide have reported substantial reductions in body weight, alongside improvements in several metabolic measures.

Research is continuing to evaluate its long-term effectiveness, safety and potential applications.

Important Information:

Retatrutide is an investigational compound and is not currently approved for general medical use. Its safety and effectiveness continue to be evaluated through clinical research.